The Senate is starting deliberations on US Food and Drug Administration funding for fiscal year 2023 from a less generous stance than the House of Representatives, setting the stage for negotiations over potentially wide differences before 1 October, when the new spending plan would start.
Both would give increases to the agency, but the Senate proposal is more conservative. The current Senate figures, outlined in...







